Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 24502535)

1.

The role of Budesonide-MMX in active ulcerative colitis.

Gionchetti P, Praticò C, Rizzello F, Calafiore A, Capozzi N, Campieri M, Calabrese C.

Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):215-22. doi: 10.1586/17474124.2014.887437. Epub 2014 Feb 6. Review.

PMID:
24502535
2.

Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

Danese S, Siegel CA, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2014 May;39(10):1095-103. doi: 10.1111/apt.12712. Epub 2014 Mar 19. Review.

PMID:
24641622
3.

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ.

Gut. 2014 Mar;63(3):433-41. doi: 10.1136/gutjnl-2012-304258. Epub 2013 Feb 22.

4.

Novel extended release budesonide formulation for treatment of ulcerative colitis.

Farkas K, Molnár T.

Expert Opin Pharmacother. 2014 Jan;15(1):131-7. doi: 10.1517/14656566.2014.860444. Epub 2013 Nov 13. Review.

PMID:
24219763
5.

Budesonide multi-matrix system formulation for treating ulcerative colitis.

Prantera C, Scribano ML.

Expert Opin Pharmacother. 2014 Apr;15(6):741-3. doi: 10.1517/14656566.2014.884072. Epub 2014 Feb 3.

PMID:
24484392
6.

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd.

Gastroenterology. 2012 Nov;143(5):1218-26.e1-2. doi: 10.1053/j.gastro.2012.08.003. Epub 2012 Aug 11.

PMID:
22892337
7.

Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.

D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P.

J Crohns Colitis. 2010 Jun;4(2):153-60. doi: 10.1016/j.crohns.2009.09.007. Epub 2009 Oct 24.

PMID:
21122499
8.

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.

Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S.

Aliment Pharmacol Ther. 2015 Mar;41(5):409-18. doi: 10.1111/apt.13076. Epub 2015 Jan 15.

PMID:
25588902
9.

Oral budesonide for induction of remission in ulcerative colitis.

Sherlock ME, Seow CH, Steinhart AH, Griffiths AM.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD007698. doi: 10.1002/14651858.CD007698.pub2. Review.

PMID:
20927762
10.

Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?

De Cassan C, Fiorino G, Danese S.

Dig Dis. 2012;30(4):368-75. doi: 10.1159/000338128. Epub 2012 Jul 12. Review.

PMID:
22796798
11.

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.

D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.

Aliment Pharmacol Ther. 2006 Oct 1;24(7):1087-97.

12.

Budesonide for ulcerative colitis.

Marín-Jiménez I, Peña AS.

Rev Esp Enferm Dig. 2006 May;98(5):362-73. Review. English, Spanish.

13.

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.

Iborra M, Alvarez-Sotomayor D, Nos P.

Clin Exp Gastroenterol. 2014 Feb 5;7:39-46. doi: 10.2147/CEG.S34715. eCollection 2014. Review.

14.

Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.

Gross V.

Expert Opin Pharmacother. 2008 May;9(7):1257-65. doi: 10.1517/14656566.9.7.1257. Review.

PMID:
18422482
15.
16.

Budesonide in the treatment of inflammatory bowel disease.

Silverman J, Otley A.

Expert Rev Clin Immunol. 2011 Jul;7(4):419-28. doi: 10.1586/eci.11.34. Review.

PMID:
21790284
17.

Oral locally active steroids in inflammatory bowel disease.

Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M.

J Crohns Colitis. 2013 Apr;7(3):183-91. doi: 10.1016/j.crohns.2012.06.010. Epub 2012 Jul 10. Review.

18.

Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn's disease.

Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Chiesara F, Papi C.

Curr Clin Pharmacol. 2012 May;7(2):131-6. Review.

PMID:
22432845
19.

Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.

Ahmadi F, Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Mahzouni P, Dorkoosh F.

Drug Deliv. 2011 Feb;18(2):122-30. doi: 10.3109/10717544.2010.520352. Epub 2010 Oct 18.

PMID:
20954795
20.

Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.

Kolkman JJ, Möllmann HW, Möllmann AC, Penã AS, Greinwald R, Tauschel HD, Hochhaus G.

Drugs Today (Barc). 2004 Jul;40(7):589-601.

PMID:
15510233
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk